ScreenerHero

NEUPNeuphoria Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · neuphoriatx.com
3.910USD-0.51%Mkt Cap: 21.13M $P/E: —

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap21.13M $
Enterprise Value1.94M $
Revenue (TTM)-13.27K $
Gross Profit-13.27K $
Net Income (TTM)-17.43M $
Revenue/Share-0.0040 USD
Last Price3.910 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.63
PEG—
EV/EBITDA-0.14
EV/Revenue-146.34
P/S-1609.10
P/B0.72
EPS (TTM)-7.90
EPS (Forward)-2.43
52W Range
3.1904% of range21.40
52W High21.40 USD
52W Low3.190 USD
Profitability
Gross Margin0.00%
Oper. Margin110513.32%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-62.90%
ROA-27.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.68M $
CapEx (TTM)—
FCF Margin77024.19%
FCF Yield-48.36%
Net Debt-19.41M $
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.02
Current Ratio14.31
Quick Ratio13.91
Book Value/Sh5.472 USD
Cash/Share3.597 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateDec 24, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.40M
Float4.19M
Insiders7.70%
Institutions61.41%
Short Interest
Short Ratio0.1d
Short % Float1.22%
Short % Out.1.21%
Shares Short65.54K
Short (prev mo.)15.83K
Technical
SMA 503.893 (+0.4%)
SMA 2004.324 (-9.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)311.22K
Avg Vol (10d)46.49K
Technical Indicators
RSI (14)52.4
MACD0.0004
MACD Signal-0.0239
MACD Hist.+0.0243
BB Upper3.999 USD
BB Middle3.859 USD
BB Lower3.719 USD
BB Width7.24%
ATR (14)0.1923 USD
Vol Ratio (20d)0.41x